Protocol Ledger

NCT06702618 · Phase II · ACTIVE NOT RECRUITING

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT06702618 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-20 Enrollment: 33 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06702618
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06702618
Protocol FieldVerified Registry Value
NCT IdentifierNCT06702618
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment33 participants (ESTIMATED)
Registered Start Date2025-02-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06702618
Hospital Research SiteLocationSite Profile
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
Liaoning Cancer HospitalShenyang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI